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Abstract
Background: Pregnancy is associated with widespread change in metabolism, which may be more marked in
obese women. Whether lifestyle interventions in obese pregnant women improve pregnancy metabolic profiles remains
unknown. Our objectives were to determine the magnitude of change in metabolic measures during obese pregnancy,
to indirectly compare these to similar profiles in a general pregnant population, and to determine the impact of a lifestyle
intervention on change in metabolic measures in obese pregnant women.
Methods: Data from a randomised controlled trial of 1158 obese (BMI ≥ 30 kg/m2) pregnant women recruited from six
UK inner-city obstetric departments were used. Women were randomised to either the UPBEAT intervention, a tailored
complex lifestyle intervention focused on improving diet and physical activity, or standard antenatal care (control group).
UPBEAT has been shown to improve diet and physical activity during pregnancy and up to 6-months postnatally in
obese women and to reduce offspring adiposity at 6-months; it did not affect risk of gestational diabetes (the primary
outcome). Change in the concentrations of 158 metabolic measures (129 lipids, 9 glycerides and phospholipids, and 20
low-molecular weight metabolites), quantified three times during pregnancy, were compared using multilevel models.
The role of chance was assessed with a false discovery rate of 5% adjusted p values.
Results: All very low-density lipoprotein (VLDL) particles increased by 1.5–3 standard deviation units (SD) whereas
intermediate density lipoprotein and specific (large, medium and small) LDL particles increased by 1–2 SD, between 16
and 36 weeks’ gestation. Triglycerides increased by 2–3 SD, with more modest changes in other metabolites. Indirect
comparisons suggest that the magnitudes of change across pregnancy in these obese women were 2- to 3-fold larger
than in unselected women (n = 4260 in cross-sectional and 583 in longitudinal analyses) from an independent,
previously published, study. The intervention reduced the rate of increase in extremely large, very large, large and
medium VLDL particles, particularly those containing triglycerides.
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Conclusion: There are marked changes in lipids and lipoproteins and more modest changes in other metabolites
across pregnancy in obese women, with some evidence that this is more marked than in unselected pregnant women.
The UPBEAT lifestyle intervention may contribute to a healthier metabolic profile in obese pregnant women, but
our results require replication.
Trial Registration: UPBEAT was registered with Current Controlled Trials, ISRCTN89971375, on July 23, 2008 (prior
to recruitment).
Keywords: Pregnancy, obesity, metabolomics, lifestyle intervention, RCT
Background
Normal pregnancy is associated with marked changes in
maternal metabolism, much of which is essential for
healthy fetal growth and development, but may lead to ad-
verse pregnancy, perinatal and longer term maternal and/or
offspring outcomes if there is substantial deviation from
physiological gestational levels [1–4]. It has been suggested
that the metabolic changes seen in normal pregnancy differ
in women who are obese and that these changes mediate at
least some of the adverse short- and long-term outcomes
associated with obese pregnancy [1, 5–8].
Randomised controlled trials (RCTs) in pregnant
women have suggested some beneficial effect of lifestyle
interventions on maternal gestational weight gain and
adiposity [9, 10], but whether this improves their meta-
bolic profiles is unclear. A recent RCT of a diet and
physical activity lifestyle intervention in 376 obese
(body mass index (BMI) ≥ 30 kg/m2) pregnant women
found beneficial effects on gestational weight gain and
C-reactive protein, but no evidence of benefit on insu-
lin sensitivity/glucose tolerance or standard lipid (total
cholesterol, very low-density lipoprotein (VLDL) chol-
esterol, low-density lipoprotein (LDL) cholesterol,
high-density lipoprotein (HDL) cholesterol or triglycer-
ide) measurements [11]. However, biomarkers were
only assessed at two time points and analyses did not
look at longitudinal change but treated results for each
time-point as independent outcomes.
The UK Pregnancies Better Eating and Activity Trial
(UPBEAT) RCT tested the effect of an intense behaviour
change intervention in 1555 obese pregnant women (BMI
≥ 30kg/m2) on adverse pregnancy and perinatal outcomes
[10]. The intervention was effective in reducing self-re-
ported dietary intake of total energy, total fat, saturated fat
and carbohydrates, as well as achieving a diet with a lower
glycaemic load and index, and increasing protein and fibre
intake as assessed at 28 weeks’ gestation [10]. Additionally,
it led to a modest increase in the time spent walking and
in the metabolic equivalent ratio of activity to rest, as well
as reductions in gestational weight gain and adiposity, but
it did not have an effect on the primary outcomes of gesta-
tional diabetes (GDM) or large for gestational age (LGA)
neonates [10]. The addition of repeat (three occasions)
gestational metabolic measurements in participants from
this RCT provides a unique opportunity to determine the
gestational metabolic profile in obese women and whether
an intervention with known beneficial effects on diet,
physical activity and adiposity influences this profile.
The aims of this study were to determine (1) how
metabolic profiles change over gestation in obese preg-
nant women and (2) to assess the effects of an interven-
tion that resulted in a healthier diet, increased physical
activity, reduced gestational weight again and reduced
adiposity in obese pregnant women, on change in gesta-
tional metabolic profiles.
Methods
Study design, randomisation and participants
UPBEAT was a multicentre RCT of a complex behav-
ioural intervention of diet and physical activity advice
versus standard antenatal care in obese pregnant women
to prevent GDM and delivery of LGA neonates [10]. It
involved eight inner-city centres in London (three cen-
tres), Bradford, Glasgow, Manchester, Newcastle and
Sunderland. Approvals were obtained from the UK re-
search ethics committee (UK integrated research appli-
cation system, reference 09/H0802/5) and local Research
and Development departments in participating centres
approved participation of their respective centre; all
women provided written informed consent prior to en-
tering the study. UPBEAT is registered with Current
Controlled Trials, ISRCTN89971375.
UPBEAT recruited and randomised 1555 obese
women (BMI ≥ 30 kg/m2), aged 16 years or older and
with a singleton pregnancy between 15+0 and 18+6
weeks of gestation (hereafter weeks). Exclusion criteria
were multiple pregnancy, current use of metformin, un-
willing or unable to provide written informed consent,
or underlying medical disorders [10]. Women were ran-
domised using an internet-based, computer-generated
sequence that ensured concealment. In order to reduce
differences between groups occurring by chance, the
randomisation procedure included minimising by age,
ethnic origin, centre, BMI and parity [10]. During preg-
nancy, women were followed up at 27+0 to 28+6 weeks
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(when an oral glucose tolerance test (OGTT) was com-
pleted) and at 34+0 to 36+0 weeks.
For the purposes of this study, women from two cen-
tres (King’s College Hospital, London, and Sunderland)
were excluded as no blood samples were taken from par-
ticipants in these centres for resource and logistical rea-
sons (n = 360 in total; 178 and 182, respectively, from
control and intervention arm were excluded). From the
remaining six centres, all women with at least one meta-
bolic profile assessment were included. Of the 1194 from
the remaining six centres, 1158 (97%) had at least one
set of nuclear magnetic resonance (NMR) metabolic
measurements together with complete data on all cov-
ariables and were included in our analyses; proportions
included were similar for the intervention and control
groups (Fig. 1).
Metabolic profiling
Venous blood samples were taken on three occasions – at
recruitment, prior to randomisation (median (IQR) gesta-
tional age, 17.0 (16.1–17.9) weeks), post-randomisation at
the time of the OGTT (27.7 (27.3–28.1)), and during the
third trimester (34.7 (34.3–35.1)). Samples taken prior to
randomisation and in the third trimester were non-fasting;
those taken as part of the OGTT were after an overnight
fast. All blood samples were initially kept on dry ice, proc-
essed within 2-hours and then stored at – 80 °C until
metabolic profiling was performed. Metabolic analyses
were undertaken on serum in two batches (March 2015
and August 2015), with samples from the three timepoints
randomly distributed across these batches. Sample pro-
cessing was automated with a Gibson 215 liquid proces-
sor. The complete process is illustrated in Additional file
1: Figure S1. A total of 158 metabolic features were mea-
sured and quantified using an NMR targeted platform
(http://www.computationalmedicine.fi/), including 129
lipid measures (lipoprotein particle subclasses, particle
size, cholesterols, fatty acids and apolipoproteins), 9 glyc-
erides and phospholipids, and 20 low-molecular weight
metabolites including branched-chain and aromatic amino
acids, glycolysis-related markers, and ketone bodies [12].
This platform has been used in several large-scale epi-
demiological studies [4, 13–16] and further details and a
full list of the 158 metabolites are presented in Additional
file 1: Figure S1, Box S1 and Table S1. All blood samples
were processed by laboratory technicians blinded to par-
ticipant data, including the allocated randomisation arm.
Statistical analyses
Full details of the statistical modelling are provided in
Additional file 1: Box S1. Multilevel (random intercept
and random slope) models were used to analyse the re-
peatedly assessed metabolic traits [17, 18]. We restricted
the timeframe of these models to 16–36 weeks so that
we were not predicting beyond available data. These
models provide an individual (predicted) level of each
metabolite at 16 weeks (the intercept) and an individual
slope, which we present as the change in each metabol-
ite per 4-week increase in gestational age between 16
and 36 weeks. In all analyses, we controlled for the mini-
mising variables used in randomisation (BMI, ethnicity,
parity, age and clinic centre) [10]. An interaction term
between time (gestational weeks) and randomised arm
(control or intervention) was also included.
We focus our discussion and interpretation of all results
on the magnitude of the point estimates (i.e. pregnancy
change in metabolites or effect of the intervention) and
their precision (i.e. 95% confidence intervals) as recom-
mended by the American Statistics Society and others [19–
21]. We explore the role of chance by providing p values
Fig. 1 Participant flow
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after controlling for multiple testing using the false discov-
ery rate using the method of Benjamini and Hochberg [22].
Change in metabolic profiles across pregnancy in obese
women in the control arm
We present the change in metabolic profiles between
16 and 36 weeks in standard deviation (SD) units in
women who were randomised to the control arm of the
trial. SD units were used to aid comparison of results
between metabolites and with those from other studies.
We also present the mean absolute differences in the
original units of measure for each metabolite (mostly
mmol/L) in the control arm. The full model results
(mean intercept and mean slope per 4 weeks) for each
metabolite in their original units are also presented for
all 1158 women included in the analyses. As the model
includes a term for the randomised arm for each
woman, these can be interpreted as the mean level of
each metabolite at 16 weeks, and its change per 4
weeks of gestation between 16 and 36 weeks having ad-
justed for any effect of the intervention. The slope is
therefore an indication of mean rate of change in me-
tabolites in obese women in general (i.e. without any
intervention effect).
Effect of the intervention on change in metabolic profiles
across pregnancy
In the main analyses, we present the effect of the inter-
vention on rate of change in metabolites in SD units per
4 weeks (using the SD value of the control group), for
ease of interpretation and to enable the effects of the
intervention to be compared across different metabolic
measures. We also present the difference in mean rate
of change in original units (mostly mmol/L per 4 weeks).
We present exact p values for all results and focus our
discussion of the effect of the intervention on point esti-
mates and confidence intervals as recommended by the
American Statistics Society [19]. We also indicate the
role of chance by indicating, in figures, which results
reached conventional p < 0.05 levels of statistical signifi-
cance after controlling the false discovery rate using the
method of Benjamini and Hochberg to deal with mul-
tiple testing [22].
Analysis assumptions and sensitivity analyses
Repeat metabolite assessments occurred at three
time-points within a narrow range of gestational ages,
such that there are gaps of up to 10 weeks with no (or
very little) data between each of the measurements
(Additional file 1: Figure S2). Therefore, we had to use
linear spline methods and could not explore smoothing
methods or use fractional polynomials to determine the
exact shape of metabolic trait change over pregnancy
[18]. Furthermore, our main analyses assume that the
effect of the intervention is consistent between the first
two measurements (~16–28 weeks) and the second two
(~28–36 weeks). To test this assumption, we modified
the multilevel model to include the possibility that the
magnitude of metabolite change might alter at 28 weeks,
and visually compared the effect of the intervention for
each trait between 16–28 and 28–36 weeks. The linear
spline method we have used assumes the model resid-
uals to be approximately normally distributed, which
may not be the case. There is evidence that estimates of
population average change, such as those we present
here, are robust to non-normality in the residuals (for
example, see [23]); however, these methods may not deal
with skewness. Therefore, to explore this further, we
have repeated our analyses of the effect of the interven-
tion on differences in mean change of the metabolites
using generalised estimating equations with robust
standard errors and unstructured correlation matrices,
which should be robust to non-normality and (some)
misspecification of the working correlation matrices.
The robust standard errors were calculated using the
White–Huber sandwich estimator and are robust to het-
eroskedasticity. We undertook a set of 14 further sensi-
tivity analyses using different approaches to examine the
sensitivity of our conclusions to possible heteroskedasti-
city, skewness and data outliers. Additional details of the
linear spline model and its assumptions, including as-
sumptions related to missing repeat measurements, and
these additional 14 sensitivity analyses are provided in
Additional file 1: Box S1.
Indirect comparison with metabolic profiles in unselected
‘healthy’ pregnancy
We were keen to compare our findings in obese preg-
nant women to those in women not selected for being
obese. As all of the participants in our study were se-
lected for being obese, we were only able to do this in-
directly by searching the literature for other studies of
similar metabolite profiles in general populations of
pregnant women. We identified one previous study, by
Wang et al. [4], that examined cross-sectional differ-
ences using the same NMR metabolic profiles between
women of reproductive age who were pregnant and
those who were not (n = 4260 women; 322 of whom
were pregnant). In addition to those cross-sectional
analyses, longitudinal change in the metabolites was
assessed in a subgroup of women (n = 583) who were
either pregnant at baseline and not at a follow-up as-
sessment 6 years later, or were not pregnant at base-
line and were so 6 years later; the study also compared
results separately by trimester of pregnancy. We com-
pared the magnitude of longitudinal change and differ-
ences by trimester using summary data from Wang et
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al. (specifically the results shown in Figs. 1, 2, 3 and 4
of that paper) [4] with our results to obtain some
insight into whether pregnancy-related metabolic
change differed between obese and non-obese women.
Results
Participant characteristics were similar between control
and intervention arms as well as between the 97% eligible
participants who had complete data and were included in
our analyses and all eligible participants (Table 1); they
were also similar when compared to all women who were
randomised irrespective of whether or not they were from
a centre where blood sampling was undertaken (Add-
itional file 1: Table S2). All women with at least one meta-
bolic profile measure were included in this study. In total,
62% of included women had all three measurements, 22%
had two measurements and 16% had one. The proportion
of those with a metabolic profile measure decreased over
gestation in line with a small loss to follow-up in the main
RCT, but this was similar in both the intervention and
control groups (Table 1).
Change in metabolic profiles in obese pregnant women
Absolute concentrations of all lipids, phospholipids and
triglycerides in lipoprotein subclasses, with the excep-
tion of large, medium and small HDL, increased across
pregnancy from 16 to 36 weeks in the obese women
randomised to usual care (Additional file 1: Tables S3
and S4). Most of these changes were substantial, with
lipids and phospholipids in all sizes of VLDL, inter-
mediate density lipoprotein and LDL concentrations in-
creasing by 1–3 SD, and concentrations of triglycerides
in these lipoproteins increasing by 2–3 SD (Fig. 2a–c).
Concentrations of very large HDL particles increased to
between 0.3 and 0.5 SD, except for triglycerides, which
increased by 2 SD. Concentrations of most large,
medium and small HDL particles generally decreased
by modest amounts (Fig. 2c), with the exception of
a b c
Fig. 2 Mean change in metabolic measures between 16 and 36 weeks of gestation in obese pregnant women receiving standard antenatal care
(n = 577). Mean increase in standard deviation units for all metabolites that (a, b) increase or (c) decrease across pregnancy. a Mean increase in
all (extremely large, very large, large, medium, small and very small) VLDL particle concentrations; all IDL particle concentrations; all (large, medium and
small) LDL particle concentrations. b Mean increase in some (those that increased across pregnancy; very large, large, medium and small) HDL particle
concentrations; most cholesterols; all glycerides and phospholipids; both apolipoproteins; all glycolysis-related metabolites; those amino acids, ketone
bodies, fluid balance and inflammatory markers that increased across pregnancy. c Mean decrease in most (large, medium and small) HDL
particle concentrations; HDL cholesterol; degree of unsaturation of fatty acids, the percentage of total fatty acids that were docosahexaenoic
acid, omega-3, omega-6, and polyunsaturated fatty acids; some amino acids; glycerol; and albumin. Circles are the mean change in SD units
for each metabolic measure between 16 and 36 weeks’ gestation, with the horizontal lines representing the 95% CIs for this change. Numeric
results of the absolute change between 16 and 36 weeks’ gestation for each trait in SD and original units for control women only are shown
in Additional file 1: Table S3. The mean value of each trait at 16 weeks and rate of change per 4 weeks between 16 and 36 weeks’ gestation
for all women (n = 1158), with adjustment for randomised group, are shown in Additional file 1: Table S4. HDL high-density lipoprotein, IDL intermediate-
density lipoprotein, LDL low-density lipoprotein, SD standard deviation, VLDL very low-density lipoprotein
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triglycerides, which increased by 1.5–3 SD, and total
and esterified cholesterol in small HDL, which in-
creased by ~0.1 SD (Fig. 2a). Total, remnant, esterified
and free cholesterol, total triglycerides, phosphoglycer-
ides and cholines, and total, linoleic, omega-6, MUFA,
PUFA and saturated fatty acids all increased by 1.5–3
SD between 16 and 36 weeks (Fig. 2b), with more
mixed and modest changes in fatty acid ratios. VLDL
particle size increased by 0.8 SD, HDL size by 0.1 SD
and LDL particle size decreased by 0.3 SD. There were
also increases in glucose (0.5 SD), lactate (0.4 SD),
pyruvate (0.6 SD) and the inflammatory marker glyco-
protein acetyls (1.7 SD) (Fig. 2b). Alanine, glycine, his-
tadine, isoleucine, phenylalanine, creatinine and all of
the ketone bodies increased (Fig. 2b), whereas glutam-
ine, valine, tyrosine and albumin decreased (Fig. 2c).
Indirect comparisons suggest that the magnitudes of
change across pregnancy in obese women are 2- to 3-
fold larger than the difference in the same metabolic
measures on becoming pregnant (from not being
pregnant) in unselected healthy women assessed by
Wang et al. [4].
Effect of the lifestyle intervention on change in the
metabolic profiles of obese pregnant women
The intervention resulted in reductions in the rate of in-
crease of concentrations of all lipids, phospholipids and
triglycerides in extremely large, very large, large and
medium VLDL particles, except for total cholesterol and
cholesterol esters in medium VLDL (Fig. 3a, Table 2,
Additional file 1: Table S5). It also resulted in reductions
in the rate of change of VLDL particle size, triglycerides
in very large HDL, phospholipids in small HDL, and the
ratio of total triglycerides to phosphoglycerides (Fig. 3b,
Table 2, Additional file 1: Table S5). There were ef-
fects on fatty acids, with a lesser reduction in those
receiving the intervention in the proportion of all
fatty acids that were linoleic, omega-6 and polyunsat-
urated, so that levels of these beneficial fatty acids
were higher in the intervention group, and reductions
a b c
Fig. 3 Effect of the UPBEAT intervention (difference in mean rate of change for each metabolic measure in SD units per 4 weeks of gestational
age comparing those in the intervention arm to those receiving standard care) on mean rate of change in metabolic traits in SD units per 4
weeks (n = 1158). a The effect of the intervention for all (extremely large, very large, large, medium, small and very small) VLDL particle concentrations;
all IDL particle concentrations; all (large, medium and small) LDL particle concentrations. b The effect of the intervention for all (very large,
large, medium and small) HDL particle concentrations; lipoprotein particle sizes; all cholesterols; all glycerides and phospholipids; apolipoproteins; all fatty
acids (absolute concentrations and percentages of total fatty acids). c The effect of the intervention for glycolysis-related metabolites; amino acids; ketone
bodies; fluid balance and inflammatory markers. Circles are the difference in mean rate of change for each metabolic measure in SD units per 4 weeks of
gestation comparing those randomised to intervention to those randomised to control (usual antenatal care) and horizontal lines are the 95% CIs for these
differences. SDs were calculated from women in the control group. Results for the differences by randomised group for all traits in the original units (e.g.
mmol/L) together with absolute p values are shown in Additional file 1: Table S5. * Results statistically significant at the conventional p < 0.05
after controlling for the false discovery rate. HDL high-density lipoprotein, IDL intermediate-density lipoprotein, LDL low-density lipoprotein,
SD standard deviation, VLDL very low-density lipoprotein
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in the rate of increase in the proportion of saturated
fatty acids (Fig. 3b, Table 2, Additional file 1: Table
S5). Rates of increase in lactate, pyruvate and alanine
were reduced, and of acetate increased, in those ran-
domised to the intervention (Fig. 3c, Table 2, Add-
itional file 1: Table S5).
Table 1 Participant characteristics
Participants with at least one metabolic profile analysed
(analysis sample)
n = 1158a
All eligible participants in the six contributing centres
n = 1194a
Control
n = 577
Intervention
n = 581
Control
n = 593
Intervention
n = 601
BMI, n (%)
30–34.9 kg/m2 273 (47.3) 287 (49.4) 279 (47) 296 (49.3)
35–39.9 kg/m2 203 (35.2) 177 (30.5) 209 (35.2) 185 (30.8)
≥ 40 kg/m2 101 (17.5) 117 (20.1) 105 (17.7) 120 (20)
Ethnicity, n (%)
White 389 (67.4) 384 (66.1) 396 (66.8) 397 (66.1)
Asian 38 (6.6) 43 (7.4) 43 (7.3) 45 (7.5)
Black 120 (20.8) 127 (21.9) 123 (20.7) 130 (21.6)
Other 30 (5.2) 27 (4.6) 31 (5.2) 29 (4.8)
Parity, n (%)
Primiparous 260 (45.1) 257 (44.2) 266 (44.9) 265 (44.1)
Multiparous 317 (54.9) 324 (55.8) 327 (55.1) 336 (55.9)
Age, n (%)
< 25 years 97 (16.8) 85 (14.6) 100 (16.9) 90 (15)
25–29 years 141 (24.4) 165 (28.4) 147 (24.8) 169 (28.1)
30–34 years 187 (32.4) 174 (29.9) 188 (31.7) 182 (30.3)
≥ 35 years 152 (26.3) 157 (27) 158 (26.6) 160 (26.6)
Gestational diabetes, n (%)
Yes 146 (25.3) 137 (23.6) 148 (25.0) 137 (22.8)
No 366 (63.4) 344 (59.2) 370 (62.4) 351 (58.4)
Missing 65 (11.3) 100 (17.2) 75 (12.6) 113 (18.8)
Centre, n (%)
Bradford 19 (3.3) 22 (3.8) 25 (4.2) 28 (4.7)
Glasgow 130 (22.5) 132 (22.7) 131 (22.1) 134 (22.3)
Manchester 67 (11.6) 67 (11.5) 70 (11.8) 69 (11.5)
Newcastle 120 (20.8) 116 (20) 122 (20.6) 120 (20)
St George’s, London 53 (9.2) 55 (9.5) 54 (9.1) 57 (9.5)
St Thomas’s, London 188 (32.6) 189 (32.5) 191 (32.2) 193 (32.1)
First clinic visit
n (%) 538 (93.2) 545 (93.8) 593 (100.0) 601 (100.0)
Median (IQR) gestation, weeks 17.0 (16.1–17.9) 17.0 (16.1–18.0) 17.0 (16.1–17.9) 17.0 (16.1–18.0)
Second clinic visit
n (%) 500 (86.7) 477 (82.1) 591 (99.7) 598 (99.5)
Median (IQR) gestation, weeks 27.7 (27.3–28.1) 27.7 (27.3–28.1) 27.7 (27.3–28.3) 27.7 (27.3–28.1)
Third clinic visit
n (%) 407 (70.5) 374 (64.4) 524 (88.4) 485 (80.7)
Median (IQR) gestation, weeks 34.7 (34.3–35.1) 34.6 (34.3–35.1) 34.7 (34.3–35.3) 34.7 (34.3–35.3)
aThe 1158 participants whose results are in the first two columns are a subgroup of the 1194 whose results are presented in the last two columns. n number, IQR
interquartile range
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Sensitivity analyses
Though statistical power is reduced in analyses comparing
change between the first two and last two measurements,
we found that the effect of the intervention appeared
consistent on change between 16–28 and 28–39 weeks
(Additional file 1: Figure S3). Results for the effect of
the intervention on change in metabolites were the
same in our main multilevel linear spline models and
the generalised estimating equations with robust stand-
ard errors, suggesting that any non-normality or out-
liers have not notably affected our results (Additional
file 1: Figure S4).
All additional sensitivity analyses led to broadly similar
results to the main analyses, the generalised estimating
equation method and each other, with correlations be-
tween estimates from all of the different methods being
above 0.9 (Additional file 1: Table S6). There were differ-
ences in specific results that reached false discovery-cor-
rected statistical ‘significance’, with some p values being
slightly higher or lower in the sensitivity compared with
our original methods. These differences in p values
could be due to incorrect model distributional assump-
tions, influence of outliers, or because non-robust tests
are more efficient for any outcomes that are normally
distributed. Significance tests for mean differences in
extremely large and very large VLDL concentrations
between the intervention and control arm, in particular,
were very similar across the different methods (a full
set of results for all of these analyses can be found in
Additional file 2, with some additional discussion in
Additional file 1: Box S1).
Discussion
We have demonstrated marked changes across pregnancy
in lipid metabolic profiles, as well as in an inflammatory
marker, in obese pregnant women. We also found modest
changes across pregnancy in glucose, some amino acids,
ketone bodies and metabolites, potentially reflecting fluid
balance. Importantly, we have demonstrated that a lifestyle
intervention that effectively improved diet and physical
activity, and reduced gestational weight gain and adiposity
in these women, resulted in improvements in most VLDL
particles and VLDL size, in comparison to women rando-
mised to usual care. There were also effects of the inter-
vention on gestational changes in fatty acid profiles, with a
reduction across pregnancy in the proportion of fatty acids
that were linoleic, omega-6 and polyunsaturated, such that
levels of these beneficial fatty acids were higher in the
intervention group.
Strengths and weaknesses of this study
Key strengths of our study are the application of an
intention-to-treat analysis in a large, well conducted RCT,
with concealed random allocation and blinded assessment
of metabolic profiles. We have appropriately modelled re-
peat measurements. These analyses assume that any miss-
ing data on the metabolic profiles is missing at random
(i.e. that the effects of the intervention in those with some
missing metabolic profile data are the same as in those
with complete data at all three time points). Given this is
a well conducted RCT, and there was similar loss to
follow-up and proportions with metabolic profiles at each
assessment in the two arms of the trial, together with
similar baseline characteristics between the two rando-
mised arms, it is likely that this assumption is met. Whilst
three repeat assessments of metabolites across gestation
in a large RCT is unique, we were only able to fit linear
spline multilevel models because metabolites were mea-
sured on just three occasions, with very little variation in
gestational age at measurement. Therefore, fitting non-lin-
ear models, for example, using fractional polynomial or
other ‘smoothing’ methods, is not possible [17, 18]. The
consistency of findings between our main analyses, gen-
eral estimating equations and eight additional sensitivity
analyses using different methods addressing possible
non-normality, heteroskedasticity, skewness and outliers,
support the robustness of our modelling approach. Our
main analyses also assume that changes in metabolites are
linear across pregnancy between 16 and 36 weeks. We ex-
plored this by comparing change between 16 and 28
weeks to those between 28 and 36 weeks, with results be-
ing broadly consistent in these two time periods. However,
we acknowledge that statistical power for these com-
parisons between these two time periods is limited and
we cannot exclude non-linear effects across pregnancy.
Replication of our findings in a similar sized or larger
RCT is important to mitigate against these findings be-
ing due to chance. However, we are not aware of any
other study with relevant data for this replication. The
consistency of findings across similar lipoprotein sub-
classes provides some reassurance that findings are not
solely due to chance.
Strengths and weaknesses in relation to other studies
An earlier prospective cohort study of unselected (e.g. on
the basis of BMI) women that used the same metabolic
profiles (from the same NMR platform) as used here,
found that lipids and lipoproteins differed by 1 SD on
average between women who were pregnant and those
who were not, with no difference in glucose levels
between them [4]. In the subgroup of women with repeat
measurements and in whom metabolic profiles were mea-
sured at least once whilst they were pregnant and at least
once when they were not, the differences within these
women (comparing when they were and were not preg-
nant) were consistent with the cross-sectional analyses
comparing pregnant women to a separate group of
women who were not pregnant. A comparison of our
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Table 2 Effect of the UPBEAT diet and physical activity lifestyle intervention on selecteda metabolic traits; n = 1158
Difference in mean rate of change in metabolic traits per 4 weeks of gestation
between 16 and 36 weeks comparing women receiving intervention to control
group (95% confidence intervals)b
In original units (see first column) per 4 weeks,
median (IQR)
In SD units per 4 weeks,c median
(IQR)
Extremely large VLDL
Concentration of chylomicrons and extremely large
VLDL particles, mol/L
– 5.430 × 10– 12 (– 8.323 × 10– 12 to – 2.537 × 10– 12) – 0.041 (– 0.065 to – 0.018)
Total lipids in chylomicrons and extremely large
VLDL, mmol/L
– 0.001 (– 0.002 to – 5.322 × 10– 4) – 0.041 (– 0.064 to – 0.018)
Phospholipids in chylomicrons and extremely large
VLDL, mmol/L
– 1.457 × 10– 4 (– 2.287 × 10– 4 to – 6.274 × 10– 5) – 0.038 (– 0.061 to – 0.015)
Total cholesterol in chylomicrons and extremely
large VLDL, mmol/L
– 1.623 × 10– 4 (– 2.725 × 10– 4 to – 5.212 × 10– 5) – 0.032 (– 0.055 to – 0.009)
Cholesterol esters in chylomicrons and extremely
large VLDL, mmol/L
– 6.952 × 10– 5 (– 1.289 × 10– 4 to – 1.015 × 10– 5) – 0.025 (– 0.049 to – 0.002)
Free cholesterol in chylomicrons and extremely
large VLDL, mmol/L
– 9.276 × 10– 5 (– 1.468 × 10– 4 to – 3.868 × 10– 5) – 0.037 (– 0.059 to – 0.014)
Triglycerides in chylomicrons and extremely large
VLDL, mmol/L
– 8.450 × 10– 4 (– 0.001 to – 4.077 × 10– 4) – 0.043 (– 0.066 to – 0.020)
Very large VLDL
Concentration of very large VLDL particles, mol/L – 2.919 × 10– 11 (– 4.656 × 10– 11 to – 1.183 × 10– 11) – 0.033 (– 0.054 to – 0.012)
Total lipids in very large VLDL, mmol/L – 0.003 (– 0.005 to – 0.001) – 0.033 (– 0.054 to – 0.012)
Phospholipids in very large VLDL, mmol/L – 4.618 × 10– 4 (– 7.453 × 10– 4 to – 1.782 × 10– 4) – 0.032 (– 0.053 to – 0.011)
Total cholesterol in very large VLDL, mmol/L – 4.869 × 10– 4 (– 8.058 × 10– 4 to – 1.681 × 10– 4) – 0.031 (– 0.052 to – 0.009)
Cholesterol esters in very large VLDL, mmol/L – 2.409 × 10– 4 (– 4.085 × 10– 4 to – 7.328 × 10– 5) – 0.029 (– 0.051 to – 0.007)
Free cholesterol in very large VLDL, mmol/L – 2.459 × 10– 4 (– 3.986 × 10– 4 to – 9.316 × 10– 5) – 0.032 (– 0.054 to – 0.010)
Triglycerides in very large VLDL, mmol/L – 0.002 (– 0.003 to – 7.781 × 10– 4) – 0.034 (– 0.055 to – 0.012)
Large VLDL
Concentration of large VLDL particles, mol/L – 1.436 × 10– 10 (– 2.419 × 10– 10 to – 4.524 × 10– 11) – 0.028 (– 0.049 to – 0.008)
Total lipids in large VLDL, mmol/L – 0.008 (– 0.014 to – 0.003) – 0.028 (– 0.049 to – 0.007)
Phospholipids in large VLDL, mmol/L – 0.001 (– 0.003 to – 4.202 × 10– 4) – 0.027 (– 0.048 to – 0.006)
Total cholesterol in large VLDL, mmol/L – 0.002 (– 0.003 to – 3.658 × 10– 4) – 0.025 (– 0.046 to – 0.004)
Cholesterol esters in large VLDL, mmol/L – 6.322 × 10– 4 (– 0.001 to – 4.684 × 10– 5) – 0.021 (– 0.042 to 5.042 × 10– 4)
Free cholesterol in large VLDL, mmol/L – 9.788 × 10– 4 (– 0.002 to – 3.053 × 10– 4) – 0.028 (– 0.049 to – 0.007)
Triglycerides in large VLDL, mmol/L – 0.005 (– 0.009 to – 0.002) – 0.029 (– 0.050 to – 0.009)
Medium VLDL
Concentration of medium VLDL particles, mol/L – 2.706 × 10– 10 (– 5.176 × 10– 10 to – 2.363 × 10– 11) – 0.020 (– 0.041 to 4.479 × 10– 4)
Total lipids in medium VLDL, mmol/L – 0.009 (– 0.017 to – 5.203 × 10– 4) – 0.020 (– 0.040 to 0.001)
Phospholipids in medium VLDL, mmol/L – 0.002 (– 0.003 to 2.571 × 10– 5) – 0.018 (– 0.038 to 0.003)
Total cholesterol in medium VLDL, mmol/L – 0.001 (– 0.004 to 6.072 × 10– 4) – 0.012 (– 0.034 to 0.009)
Cholesterol esters in medium VLDL, mmol/L – 3.934 × 10– 4 (– 0.001 to 6.747 × 10– 4) – 0.006 (– 0.028 to 0.017)
Free cholesterol in medium VLDL, mmol/L – 0.001 (– 0.002 to – 5.763 × 10– 6) – 0.018 (– 0.039 to 0.002)
Triglycerides in medium VLDL, mmol/L – 0.006 (– 0.010 to – 0.001) – 0.023 (– 0.043 to – 0.002)
Other lipids, lipoproteins affected by the intervention
Triglycerides in very large HDL, mmol/L – 2.479 × 10– 4 (– 4.714 × 10– 4 to – 2.436 × 10– 5) – 0.024 (– 0.046 to – 0.001)
Phospholipids in small HDL, mmol/L – 0.002 (– 0.004 to – 1.363 × 10– 4) – 0.022 (– 0.042 to – 0.001)
Mean diameter for VLDL particles, nm – 0.031 (– 0.054 to – 0.008) – 0.027 (– 0.048 to – 0.007)
Serum total triglycerides, mol/L – 0.015 (– 0.031 to 8.645 × 10– 4) – 0.017 (– 0.038 to 0.003)
Mills et al. BMC Medicine           (2019) 17:15 Page 9 of 12
results to those of Wang et al. [4] indirectly suggests that
the extent of change in lipids, glucose and inflammation
across pregnancy in obese pregnant women is 2- to 3-fold
greater than the change in an unselected group of healthy
women on becoming pregnant. It also appears that the
difference in lipids and lipoproteins between the third and
second trimester observed by Wang et al. [4] was less
marked (at most 1 SD) than seen herein (up to 3 SD).
These comparisons support the hypothesis that metabolic
profiles are more markedly disrupted in obese than
non-obese pregnant women. However, some caution is re-
quired in assuming full support for this hypothesis, since
Wang et al. [4] compared pregnancy to non-pregnancy
and did not have repeat measurements during pregnancy
within the same women. The full quantification of differ-
ences in metabolic profile changes across pregnancy be-
tween obese and non-obese pregnant women requires
large prospective studies with repeat assessments of meta-
bolic profiles in both obese and healthy weight women
from the same underlying population; we are not aware of
any such study currently taking place.
Previous RCTs of lifestyle advice or metformin in
obese or overweight pregnant women have reported lit-
tle or no effect on standard lipid measurements (total,
LDL or HDL cholesterol, VLDL cholesterol or triglycer-
ides) [24–26]. Differences in intervention intensity or
type (with the previous lifestyle interventions being less
intense than that used in UPBEAT), inclusion of
overweight as well as obese women in some studies, and
the limited number of lipids and other metabolites thus
far explored make comparisons with our study difficult.
Additionally, previous studies have used a mixture of fast-
ing or non-fasting samples for metabolic measurements.
Herein, the first and third trimester samples were
non-fasting, in contrast to that from the second trimester.
In previous analyses using the same NMR platform [14],
we have shown high levels of consistency between associa-
tions of these metabolites with cardiovascular diseases
using non-fasting and fasting samples. Whilst we acknow-
ledge the limited power of these analyses, the similarity
between the changes observed from the first to second tri-
mester measures and those from the second to third tri-
mester also suggests that whether the samples are fasting
or not does not have a marked impact on the results.
Implications of our findings
The impact of the UPBEAT intervention on VLDLs that
we have shown here is potentially important for maternal
and fetal/offspring health [1, 7]. The normal pregnancy in-
crease in triglycerides and VLDL is thought to be more
marked in women who are obese in pregnancy, as our find-
ings suggest. This, in turn, may increase oxidative stress
and maternal endothelial dysfunction, which has been im-
plicated in the adverse influences of maternal obesity on
pregnancy and perinatal outcomes [7]. That the
Table 2 Effect of the UPBEAT diet and physical activity lifestyle intervention on selecteda metabolic traits; n = 1158 (Continued)
Difference in mean rate of change in metabolic traits per 4 weeks of gestation
between 16 and 36 weeks comparing women receiving intervention to control
group (95% confidence intervals)b
In original units (see first column) per 4 weeks,
median (IQR)
In SD units per 4 weeks,c median
(IQR)
Triglycerides in VLDL, mmol/L – 0.015 (– 0.028 to – 0.002) – 0.022 (– 0.042 to – 0.001)
Ratio of triglycerides to phosphoglycerides – 0.005 (– 0.009 to – 6.198 × 10– 4) – 0.022 (– 0.042 to – 0.001)
Estimated degree of unsaturation 0.001 (1.229 × 10– 4 to 0.002) 0.027 (0.006 to 0.048)
Ratio of 18:2 linoleic acid to total fatty acids, % 0.069 (0.013 to 0.126) 0.028 (0.007 to 0.049)
Ratio of omega-6 fatty acids to total fatty acids, % 0.077 (0.023 to 0.131) 0.031 (0.011 to 0.051)
Ratio of polyunsaturated fatty acids to total fatty acids, % 0.079 (0.020 to 0.138) 0.028 (0.009 to 0.047)
Ratio of saturated fatty acids to total fatty acids, % – 0.049 (– 0.083 to – 0.015) – 0.035 (– 0.058 to – 0.012)
Other traits affected by the intervention
Lactate, mmol/L – 0.017 (– 0.027 to – 0.006) – 0.037 (– 0.061 to – 0.013)
Pyruvate, mmol/L – 0.002 (– 0.003 to – 6.028 × 10– 4) – 0.039 (– 0.064 to – 0.014)
Alanine, mmol/L – 0.001 (– 0.002 to – 2.708 × 10– 5) – 0.024 (– 0.050 to 0.002)
Acetate, mmol/L 3.081 × 10– 4 (7.541 × 10– 5 to 5.408 × 10– 4) 0.035 (0.009 to 0.062)
aResults are the difference in mean rate of change of each trait in original units (2nd column) and SD units (third column) per 4-weeks of gestation between 16
and 36 weeks for selected metabolic traits where p < 0.05 after correction for multiple comparisons or because they are within the same broad group of
metabolites and/or have similar magnitudes of associations (point estimates) as other metabolites with smaller p values. Complete results for all traits assessed in their
original units, together with exact p values, are shown in Additional file 1: Table S5 and in SD units in Fig. 3 in the main paper
b95% CIs are exact and not adjusted for multiple testing
cSD units are based on the standard deviation values for each metabolite in the control group of women
HDL high-density lipoprotein, IDL intermediate-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, n number, VLDL very low-density lipoprotein, SD
standard deviation
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intervention tested in this study reduces the increase in
VLDLs and triglycerides in obese women might therefore
have benefits on the risk of adverse pregnancy and perinatal
outcomes.
Maternal gestational fatty acid status is essential for
healthy fetal development as all essential fetal fatty
acids must be obtained from mothers. Specifically, high
circulating levels of long-chain polyunsaturated fatty
acids are important for fetal development. Thus, the ef-
fect of the intervention in terms of increases in the pro-
portion of polyunsaturated fatty acids and omega-6
fatty acids suggests that any impact on maternal lipids
and fatty acids is unlikely to have an adverse impact on
the developing fetus.
Whilst the UPBEAT intervention resulted in important
beneficial changes in maternal diet, physical activity, gesta-
tional weight gain and adiposity, it did not affect the pri-
mary outcomes of GDM or LGA neonates [10]. Much
more intensive changes are likely to be required to influ-
ence these outcomes, as suggested by the null findings
from other lifestyle advice RCTs in obese or overweight
pregnant women [11, 24, 25, 27], and two recent RCTs of
the effect of metformin in obese pregnant women [26, 28].
Importantly, we have shown that the UPBEAT interven-
tion, with its impact on beneficial lifestyle change, has po-
tential beneficial effects on obese pregnant women’s lipid,
lipoprotein and fatty acid change. Interestingly, the meta-
bolic measures that the UPBEAT intervention benefits are
those that differ between women with and without GDM
[29]. Furthermore, in separate analyses [30], we have also
shown that the dietary changes made as a result of the
UPBEAT intervention persist postnatally to at least 6
months, and that the intervention results in lower levels
of adiposity in offspring at 6 months, as assessed by skin-
fold thickness.
Conclusions and potential impact
We have shown marked changes in the metabolic profiles
of obese pregnant women, with beneficial effects on VLDL
and fatty acid profiles following a lifestyle intervention
that improved their diet and physical activity. In separate
analyses [30], we have shown that dietary changes made
by the mothers as a result of this intervention persist until
at least 6 months and result in reduced adiposity in off-
spring at 6 months. With further follow-up of these par-
ticipants we will be able to explore the extent to which the
improvements in lipid profiles observed during pregnancy
persist postnatally and result in lasting health benefits.
Additional files
Additional file 1: Box S1. Description of methods for the NMR platform
used to quantify metabolic profiles, and detailed description of all
statistical methods, including assumptions of these. Table S1.
Participant characteristics with additional detail compared to Table 1 in
main paper. Table S2. Metabolic measures quantified by the NMR
platform used for this study. Table S3. Absolute difference between 16
and 36 weeks of gestation for each metabolic trait in obese pregnant
women who were randomised to the control arm of the UPBEAT RCT
(n = 577). Table S4. Mean concentration at 16 weeks of gestation and
mean rate of change in concentration per 4 weeks of gestational age
between 16 and 36 weeks of gestation for each metabolic trait in
obese pregnant women in the UPBEAT RCT (n = 115). Table S5. Effect
of the UPBEAT diet and physical activity lifestyle intervention on
metabolic profiles: difference in mean rate of change in metabolic traits
(original units) between women receiving intervention and the control
group (n = 1158). Table S6. Correlations between estimates of mean
slope from different sensitivity analyses. Figure S1. Stages and
methods used for NMR platform metabolic measures (adapted from
Wurtz et al. [12]). Figure S2. Illustration of the timing of metabolite
measurements. Figure S3. Comparison of the effect of the UPBEAT
intervention between 16 and 28 weeks of gestation and between 28
and 36 weeks of gestation (n = 1158). Figure S4. Comparison of
results from our main multilevel model analyses and sensitivity
analyses using generalised estimating equations for the effect of the
UPBEAT intervention on change in metabolites. (DOCX 2580 kb)
Additional file 2: Excel file of main analyses and sensitivity analyses
results. (XLSX 132 kb)
Abbreviations
BMI: body mass index; GDM: gestational diabetes; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; LGA: large for gestational age;
NMR: nuclear magnetic resonance; OGTT: oral glucose tolerance test;
RCT: randomised controlled trial; SD: standard deviation units; UPBEAT: UK
Pregnancies Better Eating and Activity Trial; VLDL: very low-density lipoprotein
Acknowledgements
We thank the women who participated in the UPBEAT study.
Funding
The UPBEAT trial was funded by the UK’s National Institute for Health Research
(NIHR) under its grants for applied research programme (RP-PG-0407-10452),
the Chief Scientist Office Scottish Government Health Directorates (Edinburgh)
(CZB/A/680), Guy’s and St Thomas’ Charity (1060508), Tommy’s Charity
(SC039280), and the NIHR Biomedical Research Centre at Guy’s and St
Thomas’ NHS Foundation Trust and King’s College London.
The research presented in this paper is funded by the European Research
Council under the European Union’s Seventh Framework Programme (FP7/
2007-2013) ERC grant agreement No 669545 (DevelopObese), European
Union’s Horizon 2020 research and innovation programme under grant
agreement No 733206 (LifeCycle), the US National Institute of Health (R01
DK10324), the UK Medical Research Council (MRC) (MR/L002477/1) and the
NIHR Biomedical Centre at the University Hospitals Bristol NHS Foundation
Trust and the University of Bristol. SLW is supported by the Diabetes UK Sir
George Alberti Research Training Fellowship. HM, DSF, KT and DAL work in
a Unit that receives support from the UK Medical Research Council (MC_UU_
1201/5 and MC_UU_1201/9). DAL is a NIHR Senior Investigator (NF-SI-0166-
10196) and LP is an NIHR Senior Investigator Emeritus (NI-SI-0512-10104).
The views expressed are those of the authors and not necessarily those
of the UK Medical Research Council, National Health Service, NIHR, or
Department of Health, or any other funder listed above. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Availability of data and materials
Proposals to use data from the UPBEAT are considered by the UPBEAT Scientific
Committee. In the first instance, scientists interested in using these data should
contact the UPBEAT principal investigator Prof L Poston (lucilla.poston@kcl.ac.uk).
All of the statistical code used in analyses presented in this paper is available
here https://github.com/harrietlmills/UPBEAT-effects.
Authors’ contributions
All listed authors meet the requirements for authorship. LP, ALB, DP, SMN, NS
and PTS contributed to the original UPBEAT trial design. DAL, LP, SW, SMN
Mills et al. BMC Medicine           (2019) 17:15 Page 11 of 12
and NS designed the study that is reported in this paper and obtained funds
for collection of metabolite data. DAL, KT, HM and DLSF wrote the analysis
plan and HM undertook all main analyses with input from DAL and KT; HM
and NP completed descriptive analyses for Table 1 and Additional file 1:
Table S1 and DAL, DLSF and KT for Figure S4. HM, KT and DAL interpreted
the results from the statistical analyses. DAL wrote the first draft of the paper
and coordinated updates following input from co-authors. All other authors
critically reviewed the first and subsequent drafts. All authors approved the
final version, and agree to be accountable for all aspects of the work. DAL is
the guarantor of this study.
Ethics approval and consent to participate
This research complies with the Declaration of Helsinki. Approvals were
obtained from the UK research ethics committee (UK integrated research
application system, reference 09/H0802/5) and assent to participate was
obtained from local Research and Development (R and D) departments for
each participating centre. All women provided written informed consent
prior to entering the study.
This trial is registered with Current Controlled Trials, ISRCTN89971375 (http://
www.isrctn.com/ISRCTN89971375) on July 23, 2008.
Competing interests
SMN has received research support from Roche Diagnostics and Ferring
Pharmaceuticals for research unrelated to the work presented here. DAL
has received research support from Roche Diagnostics and Medtronic for
research unrelated to the work presented here. All other authors declare
they have no conflicts of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield
House, Oakfield Grove, Bristol BS8 2BN, UK. 2Population Health Science,
Bristol Medical School, University of Bristol, Bristol, UK. 3Division of Women’s
Health, Faculty of Life Sciences and Medicine, King’s College London,
London, UK. 4School of Medicine, University of Glasgow, Glasgow, UK.
5Institute of Cardiovascular and Medical Sciences, University of Glasgow,
Glasgow, UK. 6NIHR Bristol Biomedical Research Centre, Bristol, UK.
Received: 2 January 2018 Accepted: 21 December 2018
References
1. Lawlor DA, Relton C, Sattar N, Nelson SM. Maternal adiposity--a determinant
of perinatal and offspring outcomes? Nat Rev Endocrinol. 2012;8(11):679–88.
2. Liu LX, Arany Z. Maternal cardiac metabolism in pregnancy. Cardiovasc Res.
2014;101(4):545–53.
3. Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynecol.
2007;50(4):938–48.
4. Wang Q, Wurtz P, Auro K, Makinen VP, Kangas AJ, Soininen P, Tiainen M,
Tynkkynen T, Jokelainen J, Santalahti K, et al. Metabolic profiling of pregnancy:
cross-sectional and longitudinal evidence. BMC Med. 2016;14:205.
5. Lawlor DA. The Society for Social Medicine John Pemberton Lecture 2011.
Developmental overnutrition--an old hypothesis with new importance? Int J
Epidemiol. 2013;42(1):7–29.
6. Nelson SM, Matthews P, Poston L. Maternal metabolism and obesity:
modifiable determinants of pregnancy outcome. Hum Reprod Update.
2010;16(3):255–75.
7. Huda SS, Brodie LE, Sattar N. Obesity in pregnancy: prevalence and
metabolic consequences. Semin Fetal Neonatal Med. 2010;15(2):70–6.
8. Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N. Maternal
obesity is associated with dysregulation of metabolic, vascular, and
inflammatory pathways. J Clin Endocrinol Metab. 2002;87(9):4231–7.
9. Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T,
Tomlinson JW, Kunz R, Mol BW, Coomarasamy A, Khan KS. Effects of
interventions in pregnancy on maternal weight and obstetric outcomes:
meta-analysis of randomised evidence. BMJ. 2012;344:e2088.
10. Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, Hayes L,
Khazaezadeh N, Nelson SM, Oteng-Ntim E, et al. Effect of a behavioural
intervention in obese pregnant women (the UPBEAT study): a multicentre.
randomised controlled trial. Lancet Diabetes Endocrinol. 2015;3(10):767–77.
11. Renault KM, Carlsen EM, Haedersdal S, Nilas L, Secher NJ, Eugen-Olsen J,
Cortes D, Olsen SF, Halldorsson TI, Norgaard K. Impact of lifestyle
intervention for obese women during pregnancy on maternal metabolic
and inflammatory markers. Int J Obes (Lond). 2017;41(4):598–605.
12. Wurtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M.
Quantitative serum NMR metabolomics in large-scale epidemiology: a
primer on –omic technology. Am J Epidemiol. 2017;186(9):1084–96.
13. Wang Q, Wurtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, Tiainen
M, Tynkkynen T, Joensuu A, Havulinna AS, et al. Effects of hormonal
contraception on systemic metabolism: cross-sectional and longitudinal
evidence. Int J Epidemiol. 2016;45(5):1445–57.
14. Wurtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T,
Ghorbani A, Artati A, Wang Q, Tiainen M, et al. Metabolite profiling and
cardiovascular event risk: a prospective study of 3 population-based cohorts.
Circulation. 2015;131(9):774–85.
15. Wurtz P, Wang Q, Niironen M, Tynkkynen T, Tiainen M, Drenos F, Kangas AJ,
Soininen P, Skilton MR, Heikkila K, et al. Metabolic signatures of birthweight
in 18 288 adolescents and adults. Int J Epidemiol. 2016;45(5):1539–50.
16. Wurtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, Tiainen M,
Perola M, Tillin T, Hughes AD, et al. Metabolomic Profiling of Statin Use and Genetic
Inhibition of HMG-CoA Reductase. J Am Coll Cardiol. 2016;67(10):1200–10.
17. Howe LD, Tilling K, Matijasevich A, Petherick ES, Santos AC, Fairley L, Wright J,
Santos IS, Barros AJ, Martin RM, et al. Linear spline multilevel models for
summarising childhood growth trajectories: A guide to their application using
examples from five birth cohorts. Stat Methods Med Res. 2016;25:1854–74.
18. Tilling K, Macdonald-Wallis C, Lawlor DA, Hughes RA, Howe LD. Modelling
childhood growth using fractional polynomials and linear splines. Ann Nutr
Metab. 2014;65(2-3):129–38.
19. Wasserstein RL, Lazar NA. The ASA's statement on p-values: context, process, and
purpose. Am Stat. 2016;70(2):129–33. https://doi.org/10.1080/00031305.2016.1154108.
20. Sterne JAC, Davey Smith G. Shifting the evidence - what's wrong with
significance tests? BMJ. 2001;322:226–31.
21. Altman D, Machin D, Bryant T, Hanley J. Statistics with confidence. Second
edition ed. London: BMJ Books; 2000.
22. Benjamini J. Discoverying the false discovery rate. J Royal Stat Soc B. 2010;
72:405–16.
23. Warrington NM, Tilling K, Howe LD, Paternoster L, Pennell CE, Wu YY,
Briollais L. Robustness of the linear mixed effects model to error distribution
assumptions and the consequences for genome-wide association studies.
Stat Appl Genet Mol Biol. 2014;13(5):567–87.
24. Moran LJ, Fraser LM, Sundernathan T, Deussen AR, Louise J, Yelland LN,
Grivell RM, Macpherson A, Gillman MW, Robinson JS, et al. The effect of an
antenatal lifestyle intervention in overweight and obese women on
circulating cardiometabolic and inflammatory biomarkers: secondary
analyses from the LIMIT randomised trial. BMC Med. 2017;15:32.
25. McCarthy EA, Walker SP, Ugoni A, Lappas M, Leong O, Shub A. Self-
weighing and simple dietary advice for overweight and obese pregnant
women to reduce obstetric complications without impact on quality of life:
a randomised controlled trial. BJOG. 2016;123(6):965–73.
26. Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, Walker BR,
Quenby S, Wray S, Weeks A, et al. Effect of metformin on maternal and fetal
outcomes in obese pregnant women (EMPOWaR): a randomised, double-
blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(10):778–86.
27. Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, Crowther CA,
Wittert G, Owens JA, Robinson JS. Antenatal lifestyle advice for women who are
overweight or obese: LIMIT randomised trial. BMJ. 2014;348:g1285.
28. Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides
A, Shehata H. Metformin versus Placebo in Obese Pregnant Women without
Diabetes Mellitus. N Engl J Med. 2016;374(5):434–43.
29. White SL, Dharmintra P, Sattar N, Nelson SM, Lawlor DA, Briley AL, Seed PT,
Welsh P, Poston L. on behalf of the UPBEAT Consortium. Metabolic profiling
of gestational diabetes in obese women during pregnancy. Diabetologia.
2017;60(10):1903–12.
30. Patel N, Godfrey K, Pasupathy D, Levin J, Flynn A, Hayes L, Briley A, Bell R,
Lawlor DA, Oteng-Ntim E, et al. Infant adiposity following a randomised
controlled trial of a behavioural intervention in obese pregnancy. Int J Obes.
2017;41(7):1018–26.
Mills et al. BMC Medicine           (2019) 17:15 Page 12 of 12
